JU Open Plus

📖 The October issue of the Journal of Urology Open Plus is now available!

This month explores the power of collaboration, innovation and patient-centered care, featuring research on AI-assisted microsurgery, prostate cancer outcomes, vesicoureteral reflux treatment, early-onset bladder cancer and more. Plus, editorial perspectives examine emerging topics ranging from health information-seeking behavior to improving patient-reported outcomes.

Dive into the latest research shaping the future of urology! tnyp.me/OLUpTOOy/x

🚨 Why Are Patients Returning to the ED after Urologic Surgery?

A study examined unplanned ED visits within 7 days post-outpatient urologic surgery and their impact on patient care.

🔍 Key Findings
3.4% of surgeries led to ED visits.
Most visits were due to fever/sepsis (21%) or urinary retention (16%).
Only 34.5% contacted their urology service first.

🚑 Implications
Enhanced monitoring and interventions may reduce ED visits and improve outcomes.

#Urology #HealthCare #PatientCare

tnyp.me/ExDMBJLt/x

🔍 Can Micro-Ultrasound Sagittal Length Improve Prostate Cancer Predictions?

A study investigates using micro-ultrasound sagittal lesion length to better predict significant prostate cancer in high-risk patients.

🔢 Threshold Accuracy - A 2.1 cm length boosts PPV to 91.6%
📈 Predictive Increase - Each cm increase raises cancer odds by 8.7%
📉 Limitations - Length not independent predictor after adjustments

#ProstateCancer #MicroUltrasound #Imaging tnyp.me/4o5Oxzgb/x

🔍 Can We Improve Bladder Cancer Care?

A study examines optimal care coordination for #LocalizedBladderCancer in the US, revealing critical barriers and solutions for better outcomes.

👥 Multidisciplinary Collaboration - Essential for effective BC management
🔗 Coordination - Key to overcoming care fragmentation
📚 New Recommendations - 10 strategies to enhance care quality

tnyp.me/i3OZzugL/x

🔬 Can Early-Onset Bladder Cancer Hold the Key to New Treatments?

A recent study profiles the genetic landscape of early-onset bladder cancer, identifying key mutations that could guide personalized therapies.

🧬 Distinct Mutations - Younger patients show high TP53 (83%) and FGFR3 (45%) mutation rates, highlighting unique pathways.
🎯 Potential Targets - Findings suggest FGFR3 mutations as actionable therapeutic opportunities in young patients.
🚹 Demographic Insights - Predominantly male cohort with lower smoking rates compared to older counterparts.

#BladderCancer #Genomics #PrecisionMedicine tnyp.me/TohgPQEI/x